ProteinQure raises $11M in Series A funding, led by Tom Williams of Heron Rock Fund, to support its first clinical trial for PQ203 and advance pipeline programs.
PRIVATEMay 28, 2025
Amount Raised
$11 Million
Round Type
Series A
TorontoBiotechnologyHealth CareTherapeutics
Investors
Golden VenturesKensington CapitalTom WilliamsHeron Rock Fund
Description
ProteinQure, a Toronto-based biotechnology company, has closed $11M in Series A financing. The funding will support the initiation of its first clinical trial for PQ203 and advance additional pipeline programs in neurology and nephrology. The round was led by Tom Williams of Heron Rock Fund, with participation from Golden Ventures and Kensington Capital. This funding brings the total amount raised to $16M.
Who to call at ProteinQure, and when
A new round usually means ProteinQure is about to hire and buy. The teams that reach out first get the meeting.
An alert the day ProteinQure raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at ProteinQure, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
ProteinQure
Location
Toronto, Ontario, Canada
About
ProteinQure is a biotechnology company developing computational peptide therapeutics. They focus on designing therapeutic peptides using a proprietary platform that combines machine learning, structural biology, and atomic-level simulations. Their innovations aim to enable tissue-specific delivery and access to novel target classes in various medical fields such as oncology and neurology. The company is advancing programs for challenges like triple-negative breast cancer.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ProteinQure raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TorontoBiotechnologyHealth CareTherapeutics